ClinicalTrials.gg
CompletedNCT06038279Updated Jan 16, 2026

Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.

A Phase 1 interventional study of INI-2004 and Placebo in Allergic Rhinitis Due to Weed Pollen and Allergic Rhinitis, sponsored by Inimmune Corporation. Completed at 1 site in Australia. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Inimmune Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Rhinitis, Allergic with a site in Australia — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic · Australia.

Enrollment
3rd of 11
68 · median 30
Started
2023
the only one that year
Phase 1
4 of 13
none open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
Inimmune Corporation

Among the 13 studies in Rhinitis, Allergic with a site in Australia, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 1, and was the 11th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 13 studies in Rhinitis, Allergic with a site in Australia is open now. The open studies under Rhinitis, Allergic, anywhere →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Rhinitis, Allergic with a site in Australia as a file.
02

Study summary

This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses. This study will be conducted in two parts: Phase I single ascending dose (SAD) and Phase Ib multiple ascending dose (MAD).

Read the detailed description

This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses.

Phase I (SAD) - Healthy Participants will be enrolled and randomised to 4 dose cohorts (n=8 per cohort) to receive single ascending doses of INI-2004 or placebo (ratio 3:1 active: placebo). Dosing in each cohort will commence with two sentinels, with one of the two sentinels randomised to receive INI-2004 and the other randomised to receive placebo. The safety and tolerability of each sentinel participant will be monitored in the clinic until Day 2 and will be reviewed by the Principal Investigator (PI) prior to dosing the remainder of participants in each cohort. The decision to escalate between cohorts will be made by a safety review committee (SRC) following completion of the Day 3 visit for at least 6 out of 8 participants in the cohort. Cohorts will be dosed in an escalating order.

Phase Ib (MAD) - Phase Ib (MAD) may commence following completion of SAD Cohort 3 or SAD Cohort 4.

Up to 3 dose levels are planned to be evaluated. To be eligible for study inclusion, participants must have a positive response to the ragweed nasal allergen challenge at screening. Cohorts will be dosed in escalating order, with participants in each cohort (up to n=12 per cohort) randomised in blocks of 4 subjects to receive INI-2004 or placebo at a ratio of 3:1 (active:placebo). INI-2004 or placebo will be administered QW, commencing 2 weeks after administration of the second ragweed nasal allergen challenge.

03

Conditions studied

  • Allergic Rhinitis Due to Weed Pollen
  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is willing to refrain from consuming food or beverages containing caffeine and/or xanthene products, within 24 hours prior to check-in on Day -1.
  2. Female participants must be of non- i.e., surgically sterilised at least 6 weeks before the screening visit or .

Inclusion Criteria Phase Ib (Multiple Ascending Dose)

  1. Minimum 2 year history of ragweed-induced AR requiring pharmacotherapy (self-reported history accepted) and a positive ragweed skin prick test reaction at Screening Visit.
  2. Participant is willing to refrain from consuming food or beverages containing caffeine, within 24 hours prior to each clinic visit.
  3. Female participants must be of non-child-bearing potential i.e., surgically sterilised or postmenopausal.

Exclusion criteria

Exclusion Criteria Phase I and Phase Ib (MAD):

  1. or other reaction to the study drug or its active ingredients.
  2. Current treatment or use of any prescription medication within 14 days prior to admission to the clinic on Day -1 of active seasonal and perennial allergic rhinitis, non-allergic rhinitis, rhinosinusitis, or asthma. This includes antihistamines, asthma preventers and relievers, nasal decongestants, IN , and immunotherapy or use of over-the-counter medication/vitamins/supplements within 7 days prior to the first dose of study drug. Exceptions include , paracetamol and standard doses of multivitamins.
  3. Any clinically relevant structural nasal abnormalities, i.e., nasal septal perforation, nasal polyps, other nasal malformations or history of frequent nosebleeds, upper respiratory tract infection within 2 weeks prior to screening or first dose administration.
  4. History of recurrent migraine headaches within 4 weeks prior to screening.
  5. Positive alcohol breath, urine test, , HepC virus antibody, or antibody tests.
  6. Participant has donated blood or blood products within 3 months prior to first dose administration.
  7. Use of tobacco products or nicotine-containing products (including smoking cessation aids such as gum or patches.
  8. Participant plans to travel to an area with known environmental ragweed exposures at any time during study participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Arm 1 (SAD)- INI-2004 Dose Cohort 1

    Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).

    Drug: INI-2004

  • Experimental
    Arm 2 (SAD)- INI-2004 Dose Cohort 2

    Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).

    Drug: INI-2004

  • Experimental
    Arm 3 (SAD)- INI-2004 Dose Cohort 3

    Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).

    Drug: INI-2004

  • Experimental
    Arm 4 (SAD)- INI-2004 Dose Cohort 4

    Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).

    Drug: INI-2004

  • Placebo comparator
    Placebo

    Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).

    Drug: Placebo

  • Experimental
    Arm 1 (MAD) - INI-2004 Dose Cohort 1

    Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.

    Drug: INI-2004

  • Experimental
    Arm 2 (MAD) -INI-2004 Dose Cohort 2

    Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.

    Drug: INI-2004

  • Experimental
    Arm 3 (MAD) - INI-2004 Dose Cohort 3

    Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.

    Drug: INI-2004

  • Placebo comparator
    Placebo (MAD)

    Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.

    Drug: Placebo

Interventions

  • DrugINI-2004

    INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

  • DrugPlacebo

    The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.

    Also known as: Placebo for INI-2004

06

What researchers measure

Primary outcomes

  1. Incidence, severity and relationship of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to discontinuation of study treatment after a single ascending Dose (SAD)

    Graded using 5-point scale

    Time frame: Baseline, Day 1 then daily through to Day 7 End of Study Visit

  2. Incidence, severity and relationship of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to discontinuation of study treatment after multiple ascending doses (MAD)

    Graded using 5-point scale

    Time frame: Baseline = Day 0, Day 14, 21, 28, 35 through to Day 58 End of Study Visit

  3. Number of Participants with a Change from baseline in Vital signs measurements after a single ascending Dose (SAD)

    Pulse rate \[PR\], systolic and diastolic blood pressure \[BP\], temperature, respiratory rate.\[RR\] and oxygen saturation. Blood pressure will be measured using a sphygmomanometer, body temperature will be measured using a thermometer, Heart rate (HR) is measured using vital sign machine, respiratory rate is measured manually via 60-second count and oxygen saturation is measured using a Oximeter. All abnormal assessments measured as Clinically significant post dose will be recorded as AEs.

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  4. Number of Participants with a Change from baseline in Vital signs measurements after multiple ascending doses (MAD)

    Pulse rate \[PR\], systolic and diastolic blood pressure \[BP\], temperature, respiratory rate.\[RR\] and oxygen saturation. Blood pressure will be measured using a sphygmomanometer, body temperature will be measured using a thermometer, Heart rate (HR) is measured using vital sign machine,respiratory rate is measured manually via 60-second count.\[RR\] and oxygen saturation is measured using a Oximeter. All abnormal assessments measured as Clinically significant post dose will be recorded as AEs.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  5. Change from baseline in 12-lead electrocardiogram parameters after a single ascending Dose (SAD)

    12-lead ECGs parameters include but not limited to the measurements of ventricular HR, PR interval, RR interval, QRS duration, QT interval and QTcF. At each protocol scheduled timepoint, ECGs will be performed in triplicate with each replicate separated by at least 1 minute and the full set of triplicates completed within 5 minutes.All Clinically Significant findings post-dose will be recorded as AEs.

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  6. Change from baseline in 12-lead electrocardiogram parameters after multiple ascending doses (MAD)

    12-lead ECGs parameters include but not limited to the measurements of ventricular HR, PR interval, RR interval, QRS duration, QT interval and QTcF. At each protocol scheduled timepoint, ECGs will be performed in triplicate with each replicate separated by at least 1 minute and the full set of triplicates completed within 5 minutes.All Clinically Significant findings post-dose will be recorded as AEs.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  7. Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)

    Hematology - Blood samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse events. The severity of each AE and SAE will be graded using a 5-point scale

    Time frame: Baseline, Day 2 through to Day 7 End of Study Visit

  8. Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)

    Serum chemistry- Blood samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse event. The severity of each AE and SAE will be graded using a 5-point scale

    Time frame: Baseline, Day 2 through to Day 7 End of Study Visit

  9. Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)

    Urinalysis- Urine samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse event. The severity of each AE and SAE will be graded using a 5-point scale

    Time frame: Baseline, Day 2 through to Day 7 End of Study Visit

  10. Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)

    Hematology - Blood samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse event. The severity of each AE and SAE will be graded using a 5-point scale

    Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit

  11. Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)

    Serum chemistry- Blood samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse event. The severity of each AE and SAE will be graded using a 5-point scale

    Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit

  12. Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)

    Urinalysis- Urine samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse event. The severity of each AE and SAE will be graded using a 5-point scale

    Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit

  13. Change from baseline in Nasal symptoms after a single ascending Dose (SAD)

    Presence of itching, discomfort, rhinorrhoea, congestion and sneezing are assessed using a 10 cm visual analogue scale \[VAS\]. The participant will mark on the VAS where they rank their symptoms ranging from "no symptoms" to "worst symptoms ever experienced".

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  14. Change from baseline in Nasal symptoms after multiple ascending doses (MAD)

    Presence of itching, discomfort, rhinorrhoea, congestion and sneezing are assessed individually as a Total Nasal Symptoms Score (TNSS) at different time points pre and post-ragweed allergen challenge in the MAD portion of the study. TNSS is the sum of symptoms scores for nasal congestion, rhinorrhoea, nasal itching, and sneezing (each scored on a scale of 0 to 3 (below) with total possible score of 0 to 12. The criterion used to score each symptom is described below: 0 = none: no symptoms 1. = mild 2. = moderate 3. = severe

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  15. Change from baseline in Nasal irritancy after a single ascending Dose (SAD)

    Nasal examination

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  16. Change from baseline in Nasal irritancy after multiple ascending doses (MAD)

    Nasal examination

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  17. Change from baseline in Spirometry after a single ascending Dose (SAD)

    Peak expiratory flow \[PEF\]-Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for PEF will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for PEF is l/min.

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  18. Change from baseline in Spirometry after a single ascending Dose (SAD)

    Forced expiratory volume in 1 second \[FEV1\]- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for FEV1 will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for FEV1 is liters.

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  19. Change from baseline in Spirometry after a single ascending Dose (SAD)

    Forced vital capacity \[FVC\]- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for FVC will be summarised at each scheduled time point using descriptive statistics. Units of measurement used for FVC is liters.

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  20. Change from baseline in Spirometry after a single ascending Dose (SAD)

    Forced expiratory flow over the middle one-half of the FVC \[FEF25-75%\]- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for spirometry assessments FEF25-75% will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for FEV1/FVC is %.

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  21. Change from baseline in Spirometry after a single ascending Dose (SAD)

    FEV1/FVC ratio- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for spirometry assessments FEV1/FVC ratio will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for FEF 25%-75% is l/s.

    Time frame: Baseline, Day 1 through to Day 7 End of Study Visit

  22. Change from baseline in Spirometry after multiple ascending doses (MAD)

    Peak expiratory flow \[PEF\]- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for PEF will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for PEF is l/min.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  23. Change from baseline in Spirometry after multiple ascending doses (MAD)

    Forced expiratory volume in 1 second \[FEV1\]- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for FEV1 will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for FEV1 is liters.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  24. Change from baseline in Spirometry after multiple ascending doses (MAD)

    Forced vital capacity \[FVC\]- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for FVC will be summarised at each scheduled time point using descriptive statistics. Units of measurement used for FVC is liters.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  25. Change from baseline in Spirometry after multiple ascending doses (MAD)

    FEF25-75% - Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for FEF25-75%, will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for FEV1/FVC is %.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  26. Change from baseline in Spirometry after multiple ascending doses (MAD)

    FEV1/FVC ratio- Pulmonary function will be assessed using a handheld spirometer at the time points indicated. A minimum of 3 readings should be completed and recorded at each time point. Observed values and changes from baseline for FEV1/FVC ratio will be summarised at each scheduled time point using descriptive statistics. Unit of measurement used for FEF 25%-75% is l/s.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

Secondary outcomes

  1. Effectiveness of INI-2004 on nasal congestion will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 14, 21, 23, 28, 35, 37, 51 and 58 compared to baseline (Day 0)

    Determined by acoustic rhinometry. Acoustic rhinometry will be performed using GM Instruments. Measurements to include (at a minimum) nasal volume and cross-sectional area. Measurements will be performed for both left and right nasal cavities independently.

    Time frame: Baseline = Day 0 through to Day 58

  2. Effectiveness of INI-2004 on peak nasal inspiratory flow will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 14, 21, 23, 28, 35, 37, 51 and 58 compared to baseline (Day 0)

    Peak nasal inspiratory flow to be determined using the mean of three replicates.

    Time frame: Baseline = Day 0 through to Day 58

  3. Effectiveness of INI-2004 on nasal symptoms will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 23, 37, 51 and 58 compared to baseline (Day 0)

    Total nasal symptom score \[TNSS\] will be measured on a scale of 0 to 3 with a total possible score of 0 to 12. 0= none, no symptoms, 1= mild, 2= moderate, 3=severe.

    Time frame: Baseline = Day 0 through to Day 58

  4. Effectiveness of INI-2004 on nasal irritancy will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 23, 37, 51 and 58 compared to baseline (Day 0)

    Nasal examination- A macroscopic nasal examination will be performed, including conventional anterior rhinoscopy using an otoscope with an attached otic speculum (or nasal speculum and headlight) to assess swelling of the mucosa, erythema, and secretions. All post-dose CS events will be recorded as AEs.

    Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

  5. The effectiveness of INI-2004 on Spirometry will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 23, 37, 51, and 58 compared to baseline (Day 0) via PEF

    PEF- Unit of measurement or PEFis l/min

    Time frame: Baseline = Day 0 through to Day 58

  6. The effectiveness of INI-2004 on Spirometry will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 23, 37, 51 and 58 compared to baseline (Day 0) Via FEV1

    FEV1- FEV1 is measured in liters

    Time frame: Baseline = Day 0 through to Day 58

  7. The effectiveness of INI-2004 on Spirometry will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 23, 37, 51 and 58 compared to baseline (Day 0) via FVC

    FVC is measured in liters

    Time frame: Baseline = Day 0 through to Day 58

  8. The effectiveness of INI-2004 on Spirometry will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 23, 37, 51 and 58 compared to baseline (Day 0) via FEV1/FVC ratio

    FEV1/FVC- is measured in %

    Time frame: Baseline = Day 0 through to Day 58

  9. The effectiveness of INI-2004 on Spirometry will be assessed by response to the ragweed allergen challenge (Phase Ib [MAD] only) on Days 23, 37, 51 and 58 compared to baseline (Day 0) via FEF

    FEF 25%-75%- is measured as l/s

    Time frame: Baseline = Day 0 through to Day 58

  10. Single dose PK parameters: maximum observed concentration (Cmax)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  11. Single dose PK parameters: Time to Cmax (Tmax)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  12. Single dose PK parameters: Area under the concentration-time curve from time 0 to time t (AUC0-t)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  13. Single dose PK parameters: Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  14. Single dose PK parameters: Half-life (t1/2)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  15. Single dose PK parameters: Clearance (Cl/f)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  16. Single dose PK parameters: Volume of distribution (Vz/f)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  17. Single dose PK parameters: Area under the drug concentration-time curve from time zero infinity (AUCinf)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following single dose

    Time frame: Day 1 pre dose, then at 15 and 30 mins post-dose, then 1, 2 and 4 hours post-dose, Day 2 at 24 hours post-dose.

  18. Multiple dose PK parameters: Drug concentrations from pre-dose to 4 hours post-dose on Days 14 and 35.

    Pharmacokinetics (PK) of INI-2004 in blood plasma following multiple doses

    Time frame: Day 14 pre dose then 1, 2 and 4 hours post-dose, Day 35 pre dose then 1, 2 and 4 hours post-dose

  19. Multiple dose PK parameters: AUC0-4 on Days 14 and 35 (if data permits)

    Pharmacokinetics (PK) of INI-2004 in blood plasma following multiple doses

    Time frame: Day 14 pre dose then 1, 2 and 4 hours post-dose, Day 35 pre dose then 1, 2 and 4 hours post-dose

  20. Multiple dose PK parameters: Post-dose urine drug concentration on Day 14.

    Pharmacokinetics (PK) of INI-2004 in urine following multiple doses - decision if endpoint will be evaluated will be determined following review of plasma PK data from Phase I (SAD).

    Time frame: Urine to be collected at 0-2 hours post-dose interval on Day 14 only.

  21. Single dose PD parameters: Changes in cytokine levels in nasal secretions post-dose compared to baseline pre-dose.

    Pharmacodynamics (PD) of INI-2004 in nasal secretions following single dose

    Time frame: Baseline Day 1 pre-dose then 4, 24 and 48 hours post-dose.

  22. Single dose PD parameters: Changes in cytokine levels in plasma post-dose compared to baseline pre-dose.

    Pharmacodynamics (PD) of INI-2004 in blood plasma following single dose

    Time frame: Baseline Day 1 pre-dose then 4, 24 and 48 hours post-dose.

  23. Multiple dose PD parameters: Changes in concentrations of pro-inflammatory cytokines and nasal mediators in nasal secretions following dose administration compared to baseline pre-dose.

    Pharmacodynamics (PD) of INI-2004 in nasal secretions following multiple doses

    Time frame: Baseline pre-dose on Day 14 and 35, post-dose Days 14 and 35.

  24. Multiple dose PD parameters: Changes in concentrations of pro-inflammatory cytokines and nasal mediators in plasma following dose administration compared to baseline pre-dose.

    Pharmacodynamics (PD) of INI-2004 in blood plasma following multiple doses

    Time frame: Baseline pre-dose on Day 14 and 35, post-dose Days 14 and 35.

Other outcomes

  1. Multiple dose PD parameters: Changes from baseline of IgG

    Effects of INI-2004 in blood serum on ragweed-specific immunoglobulins following multiple doses.

    Time frame: Day 51 pre ragweed challenge.

  2. Multiple dose PD parameters: Changes from baseline of IgE

    Effects of INI-2004 in blood serum on ragweed-specific immunoglobulins following multiple

    Time frame: Day 51 pre ragweed challenge.

  3. Multiple dose PD parameters: Changes from baseline of IgE/IgG

    Effects of INI-2004 in blood serum on ragweed-specific immunoglobulins following multiple

    Time frame: Day 51 pre ragweed challenge.

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Sep 2024, 14 months.

Of 25 phase 1 interventional studies under Rhinitis, Allergic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Sep 14, 2023
StartActual
Jul 4, 2023
Primary completionActual
Sep 5, 2024
CompletionActual
Sep 5, 2024
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06038279
Lead sponsor
Inimmune Corporation
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Sep 14, 2023
Start date
Jul 4, 2023
Primary completion
Sep 5, 2024
Completion
Sep 5, 2024
Last update
Jan 16, 2026

Study contacts

JonL. Ruckle
study director · Inimmune Corp

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion